Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Rucaparib maintenance and monotherapy for ovarian cancer: trial updates

Jonathan Ledermann • 27 Sep 2019
ESMO 2019
Gynecological Cancer Ovarian Cancer Rucaparib
ARIEL2 ARIEL3 Study 10

Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Jonathan Ledermann, MD, FRCP, University College London, London, UK, discusses the use of rucaparib for both maintenance and monotherapy treatment in patients with ovarian cancer, highlighting the ARIEL3 trial (NCT01968213), ARIEL2 trial (NCT01891344) and Study 10 (NCT01482715). Here, Prof. Ledermann talks about the safety and tolerability of this PARP inhibitor in ovarian cancer.

More from Jonathan Ledermann

1:59
Trametinib: new treatment for recurrent LGSOC
Jonathan Ledermann • 27 Sep 2019
3:58
The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIA
Jonathan Ledermann • 28 Oct 2019
2:09
Rucaparib maintenance for recurrent ovarian carcinoma
Jonathan Ledermann • 30 Sep 2019
3:27
ICON8: Outcome in progression-free survival for weekly-dose paclitaxel in first-line ovarian cancer
Jonathan Ledermann • 11 Sep 2017

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals